Hepatitis B.

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Acute Hepatitis B (HBV) infection management is primarily supportive.
• HBV carriers without liver injury typically do not benefit from current therapies.
• Chronic HBV requires tailored treatment strategies based on viral activity and liver health.

Purpose of the Study:

• To review current management strategies for acute and chronic Hepatitis B.
• To compare the efficacy and indications of Interferon and Lamivudine therapies.
• To discuss treatment approaches for HBV coinfections and post-transplant scenarios.

Main Methods:

• Literature review of HBV management guidelines and clinical studies.
• Comparative analysis of Interferon and Lamivudine in chronic HBV treatment.
• Discussion of treatment protocols for special populations including cirrhotic and transplant patients.

Main Results:

• Interferon monotherapy shows a higher likelihood of HBsAg clearance than lamivudine.
• Lamivudine, an oral nucleoside analog, is better tolerated and indicated for decompensated cirrhosis and transplantation.
• Combination therapy with lamivudine and hepatitis B immune globulin (HBIG) may benefit pre-transplant patients in the replicative phase.
• Both drugs have shown utility in HBV coinfections (HCV, HDV, HIV), though data are limited.

Conclusions:

• Treatment decisions for chronic HBV depend on viral replication, liver injury, and patient-specific factors.
• Lamivudine offers broader clinical applications than interferon, especially in severe liver disease and post-transplant settings.
• Future HBV management may involve tailored combination therapies using immunomodulatory and antiviral agents.